Memory Might Want To Forget Results Of Bipolar Mania Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Company anticipates top-line data on two Phase IIa Alzheimer’s disease studies later this year.
You may also be interested in...
Memory, Roche Rewrite Deal To Support Phase IIa Trial In Schizophrenia Cognitive Impairment Treatment
Roche agrees to extra milestone payment for nicotinic alpha-7 agonist MEM 3454, but relinquishes rights to PDE4 inhibitor program.
Memory, Roche Rewrite Deal To Support Phase IIa Trial In Schizophrenia Cognitive Impairment Treatment
Roche agrees to extra milestone payment for nicotinic alpha-7 agonist MEM 3454, but relinquishes rights to PDE4 inhibitor program.
Wyeth To Evaluate PDE-10 Inhibitors For Schizophrenia Under Deal With Elbion
Wyeth separately inks deals with Nautilus Biotech and MediVas for hemophilia research.